Drugs / Hib-MenAC
last change Nov 2006 re-read 2 minutes ago

Hib-MenAC

Vaccine

Developed for
haemophilus infectious disease
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00197275 Feb → Nov 2006 diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Hib-MenAC ClinicalTrials.gov intervention name — accepted as the source's own label NCT00197275
Modality Vaccine “GSK Biologicals' Hib-MenAC (Haemophilus influenzae type b and meningococcal serogroups A and C) vaccineNCT00197275